308 related articles for article (PubMed ID: 24718366)
1. Vaccine against norovirus.
Tan M; Jiang X
Hum Vaccin Immunother; 2014; 10(6):1449-56. PubMed ID: 24718366
[TBL] [Abstract][Full Text] [Related]
2. Norovirus vaccines under development.
Lucero Y; Vidal R; O'Ryan G M
Vaccine; 2018 Aug; 36(36):5435-5441. PubMed ID: 28668568
[TBL] [Abstract][Full Text] [Related]
3. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.
Tan M; Jiang X
Nanomedicine (Lond); 2012 Jun; 7(6):889-97. PubMed ID: 22734641
[TBL] [Abstract][Full Text] [Related]
4. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.
Kocher J; Bui T; Giri-Rachman E; Wen K; Li G; Yang X; Liu F; Tan M; Xia M; Zhong W; Jiang X; Yuan L
J Virol; 2014 Sep; 88(17):9728-43. PubMed ID: 24920797
[TBL] [Abstract][Full Text] [Related]
5. Norovirus vaccine development: next steps.
Atmar RL; Estes MK
Expert Rev Vaccines; 2012 Sep; 11(9):1023-5. PubMed ID: 23151158
[No Abstract] [Full Text] [Related]
6. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.
Richardson C; Bargatze RF; Goodwin R; Mendelman PM
Expert Rev Vaccines; 2013 Feb; 12(2):155-67. PubMed ID: 23414407
[TBL] [Abstract][Full Text] [Related]
7. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.
Blazevic V; Lappalainen S; Nurminen K; Huhti L; Vesikari T
Vaccine; 2011 Oct; 29(45):8126-33. PubMed ID: 21854823
[TBL] [Abstract][Full Text] [Related]
8. Phylogenetic and biological characterizations of a GI.3 norovirus.
Zheng L; Zhang H; Ma J; Liu J; Ma S; Wang M; Huo Y
Infect Genet Evol; 2020 Nov; 85():104554. PubMed ID: 32927119
[TBL] [Abstract][Full Text] [Related]
9. Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.
Aliabadi N; Lopman BA; Parashar UD; Hall AJ
Expert Rev Vaccines; 2015; 14(9):1241-53. PubMed ID: 26224658
[TBL] [Abstract][Full Text] [Related]
10. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.
Lindesmith LC; Ferris MT; Mullan CW; Ferreira J; Debbink K; Swanstrom J; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
PLoS Med; 2015 Mar; 12(3):e1001807. PubMed ID: 25803642
[TBL] [Abstract][Full Text] [Related]
11. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
[TBL] [Abstract][Full Text] [Related]
12. Norovirus vaccines: Correlates of protection, challenges and limitations.
Melhem NM
Hum Vaccin Immunother; 2016 Jul; 12(7):1653-69. PubMed ID: 26836766
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of human noroviruses and updates on vaccine development.
Ramani S; Atmar RL; Estes MK
Curr Opin Gastroenterol; 2014 Jan; 30(1):25-33. PubMed ID: 24232370
[TBL] [Abstract][Full Text] [Related]
14. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
[TBL] [Abstract][Full Text] [Related]
15. Human noroviruses: recent advances in a 50-year history.
Atmar RL; Ramani S; Estes MK
Curr Opin Infect Dis; 2018 Oct; 31(5):422-432. PubMed ID: 30102614
[TBL] [Abstract][Full Text] [Related]
16. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
[TBL] [Abstract][Full Text] [Related]
17. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
Malm M; Vesikari T; Blazevic V
Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
[TBL] [Abstract][Full Text] [Related]
19. Genetic analyses of norovirus GII.4 variants in Finnish children from 1998 to 2013.
Huhti L; Blazevic V; Puustinen L; Hemming M; Salminen M; Vesikari T
Infect Genet Evol; 2014 Aug; 26():65-71. PubMed ID: 24837668
[TBL] [Abstract][Full Text] [Related]
20. A norovirus vaccine on the horizon?
Vinjé J
J Infect Dis; 2010 Dec; 202(11):1623-5. PubMed ID: 20979457
[No Abstract] [Full Text] [Related]
[Next] [New Search]
